KPA protesting the description of oriental medicine in specific drugs

Published: 2002-12-23 07:00:00

Updated: 2002-12-23 07:00:00

The Korea Food and Drug Administration (KFDA) has intended to newly add the following regulation in the rules on the review of application for manufacture or import of drugs and quasi-drug (Paragraph 2, Article 7; brandname), to the effect that in the case of an oriental medicine, the brandname s...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK